Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 81
- 试验地点
- 1
- 主要终点
- Proportion of patients that remain progression free, defined as progressive disease or death due to disease
研究概览
简要总结
This randomized phase I/II trial studies radiation therapy and rituximab in treating patients with stage I-II grade 1 or grade 2 follicular lymphoma. Radiation therapy uses high energy x-rays to kill cancer cells. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving radiation therapy with rituximab may kill more cancer cells.
详细描述
PRIMARY OBJECTIVE:
I. To determine if rituximab concurrently with radiation followed by maintenance rituximab offers a superior benefit over radiation alone. Specifically looking at the progression free survival.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab intravenously (IV) over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly diagnosed patients with stage I and II follicular lymphoma, pathologically confirmed at MD Anderson Cancer Center (MDACC) to be grade 1 or 2
- •Prophylactic use of lamivudine in patients that have antibody positive (+), but no active infection will be up to the treating physician
- •Absolute neutrophil count (ANC) >= 1000/mm^3; this value must be obtained within four weeks before protocol entry
- •Platelets >= 80,000/mm^3; this value must be obtained within four weeks before protocol entry
- •Hemoglobin >= 8 g/dL; this value must be obtained within four weeks before protocol entry
- •Bilirubin =< 1.5 times the upper limit of normal (ULN); this value must be obtained within four weeks before protocol entry
- •Alanine aminotransferase (ALT) =< 2 times the ULN or aspartate aminotransferase (AST) =< 2 times the ULN; these values must be obtained within four weeks before protocol entry
- •Performance status >= 2
- •Patients are required to have adequate renal function as indicated by a serum creatinine =< 2.5 mg/dL; this value must be obtained within four weeks before protocol entry
- •No prior known allergic reaction to monoclonal antibodies
- •Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study
- •Female patients must be willing to use two adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study or be post menopausal (free from menses > two years or surgically sterilized)
- •Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin [B HCG]) within 72 hours of receiving the first dose of rituximab
- •Patients must have the ability able to give informed consent
排除标准
- •Patients with active hepatitis B and/or hepatitis C infection
- •Patients with known human immunodeficiency virus (HIV) infection
- •Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved
- •Patients who had previous radiation dose to the site of the current primary disease, which would lead to violation of known radiation tolerance limit of that particular site if treated again
- •Patients with pre-existing cardiovascular disease requiring ongoing treatment; this includes: congestive heart failure III/IV as defined by New York Heart Association (NYHA); uncontrolled cardiac arrhythmia; unstable angina pectoris; and recent myocardial infarction (MI) (within 6 months)
- •Patients who are pregnant or breast-feeding
- •Patient with concurrent use of complementary or alternative medicines
- •Patients with psychiatric illness and/or social situations that would limit compliance with the study medication and requirements
研究组 & 干预措施
Arm II (radiation therapy and observation)
Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
干预措施: Radiation Therapy (Radiation)
Arm I (radiation therapy and rituximab)
Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab IV over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
干预措施: Radiation Therapy (Radiation)
Arm II (radiation therapy and observation)
Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
干预措施: Clinical Observation (Other)
Arm I (radiation therapy and rituximab)
Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab IV over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
干预措施: Rituximab (Biological)
结局指标
主要结局
Proportion of patients that remain progression free, defined as progressive disease or death due to disease
时间窗: Up to 15 years
The student t-test or the Wilcoxon rank sum test will be used to compare continuous variables between two different patient groups. The chi-square test or the Fisher's exact test will then be applied to assess the association between two categorical variables. Logistic regression will be utilized to assess the effect of patient prognostic factors on the response rate. Kaplan-Meier survival curves will also be constructed.
次要结局
- Overall survival(Up to 15 years)
- Progression free survival rate(Up to 15 years)